FMP
SIGA Technologies, Inc.
SIGA
NASDAQ
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
8.51 USD
-0.42 (-4.94%)
About
ceo
Dr. Diem Nguyen M.B.A., Ph.D.
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.siga.com
exchange
NASDAQ
Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
CIK
0001010086
ISIN
US8269171067
CUSIP
826917106
Address
31 East 62nd Street
Phone
212 672 9100
Country
US
Employee
45
IPO Date
Sep 10, 1997
Key Executives
